Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Hospitals & Diagnostics
    • IHH Healthcare extends...

    IHH Healthcare extends validity of revised offer for Fortis to June 30

    Written by Ruby Khatun Khatun Published On 2018-05-26T10:00:12+05:30  |  Updated On 26 May 2018 10:00 AM IST
    IHH Healthcare extends validity of revised offer for Fortis to June 30

    New Delhi: Malaysian firm IHH Healthcare Berhard on Friday extended the acceptance period for its enhanced revised proposal for acquiring Fortis to June 30 in the wake of changes in the board of the cash-strapped healthcare chain.


    Earlier, out of four directors whose removals were sought by two institutional investors, three directors — Harpal Singh, Sabina Vaisoha, and Tejinder Singh Shergill — had resigned ahead of an extraordinary general meeting (EGM) called to vote on the matter.


    This week, the shareholders had voted out the fourth director, Brian Tempest, from the board in the EGM held on May 22.


    “In order to enable the reconstituted board to fully consider and evaluate our proposal, we now extend the acceptance period of the enhanced revised IHH proposal until 11.59 pm on June 30,” IHH Healthcare said in a letter to the directors of Fortis Healthcare.


    IHH Healthcare, which had revised its offer to directly invest in Fortis at Rs 175 per share on May 1 from an initial non-binding offer to invest in Fortis at Rs 160 per share, had earlier stated that its enhanced offer would expire on May 29.


    The Malaysian healthcare chain is among the four suitors — Munjals-Burmans combine, TPG-Manipal combine and KKR-backed Radiant Life Care — which had put binding bids for Fortis.


    Earlier this week, Manipal-TPG combine had also extended the validity of its modified offer for Fortis Healthcare to June 6, 2018. Fortis’ board of directors is scheduled to meet on May 30 to consider and approve the audited financial results for the quarter and financial year ended March 31, 2018.


    The resignations of three directors and removal of Tempest has cast a shadow over the ongoing attempt to sell Fortis as these four directors were among the five who had voted in favour of Munjals-Burmans' Rs 1,800-crore bid for the healthcare firm.


    The board of Fortis on May 10, in a 5-3 decision, opted to go with the offer from Munjals-Burmans combine to invest Rs 1,800 crore in Fortis.


    On May 14, Manipal-TPG combine had again sweetened its offer for Fortis at Rs 180 per share, thereby increasing the valuation of the healthcare company to Rs 9,403 crore.


    Manipal-TPG combine was the first to make a binding offer for the cash-strapped healthcare chain.


    China's Fosun Healthcare was also in the race for Fortis initially, but it did not make a binding bid for the company.

    Brian TempestEGMextendsextraordinary general meetingFortisFortis HealthcareFosun HealthcareIHHIHH Healthcareinstitutional investorsManipalMunjals-Burmansrevised offerTPGvalidity
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok